Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Sarcoma

2500 - A Phase II Study of Preoperative Chemoradiation plus Sorafenib (S) for High-Risk Extremity Soft Tissue Sarcomas (STS)


22 Oct 2018


Poster Discussion session - Sarcoma


Cytotoxic Therapy;  Radiation Oncology

Tumour Site

Soft Tissue Sarcomas


Christopher Ryan


Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299


C.W. Ryan, L.E. Davis, Y. Doung, J.L. Davis, A.Y. Hung, J.B. Hayden, K.R. Gundle, J.T. Vetto, A. Mansoor, B.R. Beckett, P. Norr, S. Bertolone-Smith, W. Huang

Author affiliations

  • Knight Cancer Institute, Oregon Health Science University, 972393011 - Portland/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2500


We previously reported a phase I trial of S added to epirubicin (Epi) and ifosfamide (Ifos) with pre-op radiation (XRT) for patients (pts) with high-risk extremity STS. To further evaluate this regimen, we performed a phase II trial using a primary endpoint of pathologic necrosis rate at time of surgery.


Eligibility: >5 cm, grade 2-3, extremity / body wall STS, limb-sparing candidates. Pts with metastases (mets) who were planned for resection of primary tumor were allowed. Chemotherapy: Epi 30 mg/m2/day D1-3, Ifos 2.5 g/m2/day D1-3 with mesna and pegfilgrastim repeated every 21 days for 3 pre- and 3 post-op cycles. S 400 mg/day was initiated 14 days prior to chemotherapy and continued throughout treatment. XRT: 28 Gy in 8 fractions during cycle 2 (Epi omitted) with a post-op boost for positive margins. Dynamic contrast-enhanced (DCE-) MRI was performed to assess changes in tumor size, perfusion and permeability.


20 pts were enrolled. Median age: 54 (21-68); location: lower extremity (17), upper extremity (3); median size: 13 cm (5-30); histology: pleomorphic/NOS (11), liposarcoma (3), myxofibrosarcoma (3); synovial (2), MPNST (1). 4 pts had mets at baseline. Limb-sparing surgery was performed in all pts. Margins were positive in 4 pts (20%). Most common grade 3-4 toxicities were neutropenia (17 pts), hypophosphatemia (14), thrombocytopenia (13), anemia (13), neutropenic fever/infections (12), other infections (8), hypokalemia (6), encephalopathy (3). 10 pts (50%) had post-op wound complications requiring surgical intervention. 75% of pts completed pre-op therapy, but only 20% completed all post-op therapy. 8 tumors (40%) demonstrated ≥ 90% necrosis at surgery. There were 2 partial responses among 4 pts with mets. With a median follow-up of 27 months (10-43) among 16 pts with localized disease, 50% have developed mets. There have been no local recurrences.


While substantial tumor necrosis was achieved with this regimen, there was a high rate of distant relapse which may be influenced by small sample size. Wound complications were frequent but recoverable and side effects were similar to previously reported. Results of DCE-MRI analysis will be presented at meeting.

Clinical trial identification


Legal entity responsible for the study

Christopher W. Ryan, M.D.


Bayer (drug only).

Editorial Acknowledgement


C.W. Ryan: Drug-only support for the conduct of this study: Bayer. W. Huang: Financial interest: Imbio, LLC (a company that may have a commercial interest in the results of this research and technology). This potential individual and institutional conflict of interest has been reviewed and managed by OHSU. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.